Pregabalin Capsule
Product Images NDC 63629-8239

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 63629-8239). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636298239)

This text describes a medication called Pregabalin Capsules, USP which is available in a 225mg capsule, with the National Drug Code (NDC) of 63629-8239-01. It also provides instructions to keep the medicine away from the reach of children and the proper storage temperature range. The medication is only available through a prescription.*

FDA Label Image

Label (Lbl6362982392)

This appears to be a description of a medication or pharmaceutical product. Specifically, it is comparing "Lyrica 225mg (CV)" capsules made by ScieGen Pharmaceuticals to a similar product that has been prepackaged by Bryant Ranck. The packing includes a 30-count of capsules and instructions to store the medication at room temperature. The NDC number is listed as 6362982391, and the product is marked with the code "08239301523487."*

FDA Label Image

Figure 1 (Pregabalin Fig01)

FDA Label Image

Figure 2 (Pregabalin Fig02)

The text indicates a chart or data table showing the percentage improvement in pain from a baseline for patients who received Pregabalin 160 mg for three days. The chart lists percentage values ranging from 2% to 100%. However, the chart appears to have some missing or illegible data, as there are empty cells and some unclear numbers. Additionally, there is some unrelated text mentioning "Facebook" and some nonsensical sequences of numbers. Overall, this text provides limited information and context, so it is difficult to draw any conclusions or make recommendations based on it.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

This text appears to be a table displaying the percentage of patients improved and the level of pain improvement from various medications, including Pregabalin, administered at different doses and frequencies. The table also includes dates of measurement.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

FDA Label Image

Figure 5 (Pregabalin Fig05)

This appears to be a table showing the results of a study comparing the effectiveness of Fregabalin at 100mg three times per day and Pregabalin at 80mg three times per day, with a placebo, in improving pain levels in patients. The table shows the percentage of patients who showed improvement, and the percentage improvement in pain from baseline. Unfortunately, the has made some errors in the text, making it difficult to interpret some parts of the table.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

FDA Label Image

Figure 7 (Pregabalin Fig07)

FDA Label Image

Figure 9 (Pregabalin Fig08)

The text shows a graph indicating the percent of patients who improved on Pregabalin doses of 300mg and 450mg compared to a placebo for the treatment of pain. The graph shows that the 450mg dose had a higher percentage of patients improving than the other doses.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

This text is a table showing estimated percentage of subjects without LTR categorized by the days of treatment and the type of medication. "Progabain" and "Placebo" are the two types of medication being compared. However, there is no clear explanation of what LTR means, so a full description of the table's purpose cannot be provided.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

FDA Label Image

Figure 12 (Pregabalin Fig11)

The text appears to be a data table and does not provide enough information for a useful description.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

This text appears to be a formula for calculating the CLCT (creatinine clearance) in patients based on their age, weight, and serum creatinine levels. It mentions that for female patients, the calculation should be multiplied by 0.85. However, due to the inconsistency of the output and lack of context, it is difficult to provide a more concise or specific description.*

FDA Label Image

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.